palmitoylethanolamide.com.au
HomeResearchErin 2023

Sex differences in endocannabinoid tone in a pilot study of cannabis use disorder and acute cannabis abstinence

Erin L Martin, Nathaniel L Baker, Cristina Sempio, Uwe Christians, Jost Klawitter, Aimee L McRae-Clark. Addict Biol. 2023 Oct;28(10):e13337.

Observational studyHumans

Design
Observational study
Subjects
10 adults with moderate to severe cannabis use disorder, 5 men and 5 women
Dose used in the study
Not applicable; palmitoylethanolamide was measured in plasma, not given
Duration
Two study weeks one month apart; cannabis abstinence in the second week
What was measured
Plasma endocannabinoids and congeners including PEA, with daily reports of cannabis use and withdrawal symptoms.

What the authors reported

The study found:

  • Women reported a larger rise in withdrawal symptoms during abstinence (change 9.4, p < 0.001) than men (change 1.2, p = 0.35).
  • Sex differences in AEA, SEA and LEA appeared at the morning time point during abstinence.
  • LEA was associated with withdrawal in both sexes; PEA (beta 0.22) and 2-AG (beta 0.32) were associated with withdrawal in women only.

Limits of this study

A pilot of 10 people; findings are preliminary and cannot show cause or any effect of taking PEA. The authors have no conflicts of interest to disclose.

Source

PubMed 37753564 · doi:10.1111/adb.13337

Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.